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Abstract
(R)-Lacosamide ((R)-2, (R)-N-benzyl 2-acetamido-3-methoxypropionamide), has recently gained
regulatory approval for the treatment of partial-onset seizures in adults. Whole animal
pharmacological studies have documented that (R)-2 function is unique. A robust strategy is advanced
for the discovery of interacting proteins associated with function and toxicity of (R)-2 through the
use of (R)-2 analogs, 3, that contain “affinity bait (AB)” and “chemical reporter (CR)” functional
groups. In 3, covalent modification of the interacting proteins proceeds at the AB moiety, and
detection or isolation of the selectively captured protein occurs through the bioorthogonal CR group
upon reaction with an appropriate probe. We report the synthesis, pharmacological evaluation, and
interrogation of the mouse soluble brain proteome using 3 where the AB group is an isothiocyanate
moiety. One compound, (R)-N-(4-isothiocyanato)benzyl 2-acetamido-3-(prop-2-ynyloxy)
propionamide ((R)-9), exhibited excellent seizure protection in mice and, like (R)-2, anticonvulsant
activity principally resided in the (R)-stereoisomer. Several proteins were preferentially labeled by
(R)-9 compared with (S)-9, including collapsin response mediator protein 2.
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Epilepsy is a major neurological disorder that affects all populations.1 Epilepsy describes the
types of recurrent seizures produced by paroxysmal excessive neuronal discharges in the brain.
2,3 The mainstay of treatment has been the long-term and consistent administration of
anticonvulsant drugs.4-6 Unfortunately, current medications are ineffective for approximately
one-third of patients with epilepsy.7 Many continue to have seizures, while others experience
disturbing side effects (e.g., drowsiness, dizziness, nausea, liver damage).8 The shortcomings
of current regimens highlight the need for new agents with novel mechanisms of action. The
ability to identify specific nervous system pathways and protein target sites responsible for
seizures would accelerate the development of new and safer therapeutic agents.
In 1985, we discovered a novel class of anticonvulsant agents, termed functionalized amino
acids (FAAa, 1).9-18 The lead compound, (R)-lacosamide ((R)-2, (R)-N-benzyl 2-acetamido-3-
methoxypropionamide18), has recently gained regulatory approval for adjunctive therapy for
partial-onset seizures in adults.19 Whole animal pharmacological studies have documented that
(R)-2 function is unique and prevents seizure spread by mechanisms different from current
clinical agents.18,20 Radioligand displacement assays using more than 100 potential binding
sites, which include both ligand- and voltage-gated receptors, failed to identify high-affinity
binding targets,21 suggesting that either the target site(s) are novel or the binding is weak or
both. Only recently has (R)-2 function been reported to be correlated to the modulation of both
the slow inactivation gate of sodium channels22 and collapsin response mediator protein 2
(CRMP2).21 The full spectrum of pharmacological pathways for (R)-2 remains elusive.
aAbbreviations:
FAA functionalized amino acids
AB affinity bait
CR chemical reporter













iTRAQ isobaric tag for relative and absolute quantitation
GST glutathione-S-transferase
CNS central nervous system
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These findings have led us to suggest that (R)-2 may interact with several targets and that
(R)-2 drug efficacy is a summation of multiple beneficial interactions, similar to other
neurological agents.23 Using two antiepileptic agents as examples,24 carbamazepine interacts
with sodium channels, reduces sodium and calcium influx through N-methyl D-aspartate
(NMDA)-activated channels at glutamate receptor sites, blocks the reuptake of norepinephrine
into presynaptic terminals, and has adenosine receptor antagonistic activity. Similarly,
topiramate blocks sodium channels, enhances gamma-aminobutyric acid (GABA)A-mediated
chloride influx, acts as an antagonist to α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate
(AMPA) and kainate receptors, and inhibits carbonic anhydrase.
A major objective of our laboratories is to identify and characterize the target(s) and mechanism
(s) of (R)-2 function and to advance molecular tools useful to elucidate the pathways leading
to seizure control. Here, we report three modified (R)-2 agents each with an appended
isothiocyanate moiety that have been designed to search the brain proteome for site(s) of drug
binding. These three compounds were used to interrogate soluble mouse brain lysate. We show
that CRMP2 along with other potential lacosamide target(s) are selectively captured.
Results
a. The Proposed Method
Central to our efforts is the expansion of traditional and contemporary methods of identifying
small-molecular-weight ligand protein target sites where binding is modest and where
moderate-to-extensive ligand structural change abolishes target binding. Accordingly, we have
designed (R)-2 analogs that contain an “affinity bait (AB)” and a “chemical reporter (CR)”25
group. These compounds are defined as lacosamide AB&CR agents (R)-3. In Scheme 1, we
diagram the proposed pathway for (R)-3 function. We anticipate that (R)-3 reversibly binds to
the (R)-2 receptor(s) 4 to give 5, provided that the AB and CR moieties do not perturb binding.
This interaction is followed by an irreversible, covalent modification wherein receptor capture
occurs through the AB moiety to give 6. In most instances, the AB group is either an
electrophilic or a photoaffinity agent. Both groups have been extensively utilized to capture
biomolecular targets. Removal of the selectively captured protein 6 occurs through the
bioorthogonal25a CR group upon reaction with a probe (P, 7) to provide 8. While similar target
discovery approaches have been reported,26 few, if any, have been designed to identify
receptors of small-molecular-weight ligands (drugs) where binding does not occur at the
enzyme catalytic site. The captured (R)-2-bound target 8 in the reaction mixture (e.g., cell
lysate) is either detected by in-gel fluorescence through the use of a reporter group tethered to
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7 or is selectively removed from the mixture using affinity-based chromatographic methods
(e.g., biotin-(strept)avidin).
b. Structural and Chemical Criteria for Lacosamide AB&CR Probes ((R)-3)
Six criteria have been established for our AB&CR ((R)-3) agents. First, the compound must
conform to the structure-activity relationship (SAR) observed for 1.9-18 In this case, we must
limit the size of the AB and the CR groups because of 1’s SAR.9-18 Second, the reactive AB
group must have documented success in previous target adduction studies.27 In this report, we
describe (R)-3 agents into which an electrophilic affinity bait has been installed. For the
electrophilic AB, we expect that this group must be correctly aligned with the target-based
nucleophile if covalent modification is to take place.27 Third, the CR group must be inert under
the conditions necessary to bait the target protein yet must be prone to react with probe P.
Fourth, syntheses of both enantiomeric forms of the lacosamide AB&CR agents 3 are
necessary. A distinguishing feature of 1 is that its anticonvulsant activity resides principally in
the D-configuration.11-13,15,18 Accordingly, preferential enantioselective irreversible
inactivation with the AB&CR agents serves as an important measure of target site specificity.
28,29 Fifth, the electrophilic (photoaffinity) labels should be incorporated at different sites
within the (R)-2 structure to capture all its possible binding partners. Sixth, the (R)-3 agents
used to identify target sites should ideally demonstrate significant anticonvulsant activity in
in vivo assays (e.g., maximal electroshock (MES)-seizure test30). Documentation of similar
pharmacological activity provides preliminary evidence that the mode of action of (R)-3 is
comparable with (R)-2. We recognize that promising pharmacological data do not guarantee
that these compounds will serve as site-selective agents since the ability of the AB unit to
efficiently modify the protein targets is a composite of variables, some of which are unrelated
to function. Correspondingly, compounds inactive in vivo may still function as in vitro affinity
labels since chemical and cellular (e.g., transport, metabolic) processes may prevent ligand-
target site binding. Nonetheless, demonstrating significant and stereospecific in vivo
anticonvulsant activity provides an initial stringent test for our agents.
c. Compound Selection
In this study, we selected (R)- and (S)-9–11 as our initial AB&CR agents where AB is the
electrophilic isothiocyanate moiety.31-42 We have chosen small AB and CR groups to minimize
adverse binding of our agents with possible receptor sites. In 9 and 11, we have incorporated
the isothiocyanate moiety at the 4′ N-benzyl position. Earlier studies showed that N-benzyl 4′-
substituted 1 compounds exhibited enhanced anticonvulsant activities compared with their
corresponding 3′-isomers.43 In 9, the CR group is an alkyne, while in 11 it is an azide. In
compound 10, the sites of AB (isothiocyanate) and CR (alkyne) incorporation have been
interchanged from that in 9.
The isothiocyanate AB group displays an excellent balance between stability and reactivity; it
does not readily react with hydroxylic solvents (permitting its dissolution in aqueous solutions)
but does react with nucleophiles (e.g., thiols (cysteines), amines (lysines)).27 Significantly,
isothiocyanate electrophilic units have proven effective in selectively modifying target proteins
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(e.g., GABA,37 opioid31,34,35) within brain membrane fractions and have been used for in
vivo modification studies after intracerebroventricular administration.31c Nonetheless, the
isothiocyanate AB unit has limitations. First, only lysine and cysteine residues are likely to be
modified. This restriction may prevent covalent adduction of some receptors. Fortunately, the
extended C(α) methylene chain within lysines gives this nucleophilic amino acid considerable
conformational flexibility to reach a bound AB&CR agent. Another concern is that
hydrophobic drug binding pockets may not contain nearby lysine residues. Considerable
support exists for the selected CR moieties (i.e., alkyne, azide) groups and for the notion that
protein capture with P occurs through a Cu(I)-mediated cycloaddition reaction (“click
chemistry”).25
d. Synthesis of Agents
The synthetic pathways used to prepare 9–11 are provided in Scheme 2. Care was taken to
install the AB unit in the last step to avoid possible isothiocyanate-related reactions during the
synthesis and reaction workup. In general, commercially available D- or L-serine methyl ester
hydrochloride (12) was converted to the corresponding (R)- and (S)-methyl 1-
acetylaziridine-2-carboxylates (16), followed by stereospecific ring opening with the
appropriate alcohol using catalytic amounts of BF3•Et2O to give the desired (R)- and (S)-methyl
2-acetamido-3-(alkoxy)propanoates (17, 18).44,45 The esters 17 and 18 were converted to the
free acids 19 and 20, respectively, using stoichiometric amounts of LiOH at 0 °C. Under these
conditions, we detected little or no racemization. The free acids were coupled with the
appropriate substituted benzylamine using either the mixed anhydride coupling method46a
(i.e., isobutyl chloroformate (IBCF), N-methyl morpholine (NMM)) or 4-(4,6-
dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride (DMTMM)46b to give the
lacosamide analogs 23–25. The syntheses of 9–11 concluded with AB isothiocyanate moiety
installation. For 9 and 10, we used di(2-pyridyl) thionocarbonate (DPT)47a and for 11, 1,1′-
thiocarbonyldiimidazole (DITC).47b The spectral and analytical data for 9–11 and all
intermediates were in agreement with their proposed structures. We documented the
enantiopurity of the final compounds using the chiral resolving agent (R)-mandelic acid
and 1H NMR spectroscopy.48
In order to assess the individual effects of the AB (isothiocyanate) and CR (alkyne, azide) units
on anticonvulsant activities, the corresponding lacosamide analogs that contained only the AB
(27) or the CR (28–30) units have also been prepared (Supplementary Schemes S1-S3 in the
Supporting Information). We have previously reported the synthesis and anticonvulsant
activity for the lacosamide isothiocyanate (AB) probes (R)-31 and (S)-31.43a
Park et al. Page 5














Initial criteria we established for our lacosamide AB&CR agents are that they prove effective
in preventing MES-induced seizures in animal models30 and that the principal activity resides
in the (R)-stereoisomer (D-configuration). In the MES test, tonic hindlimb seizures are induced
by corneal electrical stimulation. This assay is an established method to identify compounds
effective against generalized tonic-clonic seizures30 and was the initial assay used to discover
(R)-2. Table 1 lists the MES anticonvulsant activities obtained for the lacosamide AB&CR
compounds (9, 11), the analogs into which only an AB (27, 31) or a CR (28–30) moiety was
installed in the lacosamide framework, (R)-2,18 and other clinical antiepileptic agents. The
compounds were also evaluated in the subcutaneous metrazol (scMet) seizure model but
provided no protection (data not shown). The absence of seizure protection in this assay is a
hallmark of 1 activity.9-18
We found that we could incorporate a small moiety in the 4′ position of the N-benzylamide
unit of (R)-2 without appreciable loss of MES anticonvulsant activity compared with
unmodified (R)-2 (MES ED50 = 4.5 mg/kg) in mice (ip). For example, excellent seizure
protection was observed for CR (R)-29 (MES ED50 = >3, <10 mg/kg) and AB (R)-31 (MES
ED50 = 24 mg/kg).43 We also found that some modifications of the C(2) side chain in (R)-2
led to excellent activity retention in the MES seizure test, while others did not. The MES
ED50 values for the CR O-propargyl ((R)-28), the CR O-2-azidoethyl ((R)-30), and the AB
O-2-isothiocyanatoethyl ((R)-27) lacosamide analogs were 16, 100-300, and >300 mg/kg,
respectively. We do not know if transport, efflux or metabolic factors are responsible for the
diminished activity for (R)-27 and (R)-30 in the MES test. Interestingly, (R)-30 showed
appreciable activity in the psychomotor seizure test49 (6 Hz ED50 = 44 mg/kg). Consistent with
the pharmacological pattern observed for 218 and other FAAs (1),11-13,15 we found that for
28, 29, and 31, the (R)-stereoisomer was consistently more potent than the (S)-stereoisomer.
The findings for the lacosamide AB and the lacosamide CR analogs guided our investigation
of 9–11 where both an AB and a CR moiety were installed in the molecule. Here, we found
that 9, containing a N-benzyl 4′-isothiocyanate moiety and an O-propargyl moiety, provided
significant seizure protection (MES ED50 = 45 mg/kg) and that activity principally resided in
the (R)-stereoisomer. For 11, we observed that both stereoisomers gave only minimal seizure
protection, a finding that mirrored the anticonvulsant activity for the corresponding CR-only
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analogs (R)-30 and (S)-30. Finally, we did not evaluate (R)-10 and (S)-10 in animal models
since the corresponding AB compounds (R)-27 and (S)-27 were inactive at 300 mg/kg.
f. Chemical Evaluation of the AB and CR Units in 3
The AB and CR moieties have been installed within 9–11 for specific chemical functions. The
isothiocyanate AB unit serves as an electrophilic agent to trap either lysine or cysteine residue
(s) situated near the (R)-2 binding site, and either the alkyne or azide CR group acts as a
bioorthogonal unit that can be selectively captured by the corresponding azide- or alkyne-
containing probe via a Cu(I)-mediated cycloaddition reaction.50,51 Prior to conducting our
studies we evaluated the chemical reactivity of these groups using model reactions (Figure 1).
Treating AB (R)-31 with EtNH2 gave the expected thiourea (R)-32 in high yield (94%).43
Substituting the aliphatic isothiocyanate 33 for (R)-31 gave the expected thiourea 34 (77%
yield).43a Correspondingly, when (R)-9 was reacted with 1.0 equiv of the biotin-containing
azide probe 35,52 CuSO4 and sodium ascorbate,50 we isolated the desired product, (R)-36, in
51% yield. No modification of the isothiocyanate moiety was observed under these Cu(I)-
mediated cycloaddition conditions. Finally, we treated aliphatic azide (R)-30 with alkyne 37
under similar conditions to obtain (R)-38 (96% yield).
g. Using Mouse Brain Soluble Lysates to Identify Lacosamide Targets
The utility of the lacosamide AB&CR agents 9–11 to identify drug binding targets was first
assessed using mouse brain soluble lysates prepared from male (2 months) ICR mice (Rockland
Immunochemicals, Gilbertsville, PA). The lysates were treated with (R)- and (S)-9–11 (5 μM)
for 0.5 h at room temperature, and the lysate mixture reacted with an appropriate rhodamine-
containing probe (39,53 40) under Cu(I)-mediated cycloaddition conditions (CuSO4, tris(2-
carboxyethyl)phosphine (TCEP)). The reaction samples were separated by electrophoresis
using a 10% SDS-PAGE gel and then analyzed for proteins labeled by the AB&CR agents by
in-gel fluorescence using a typhoon scanning laser (emission 532 nm, absorption 580 nm)
(Figure 2a). Gels were Coomassie-stained to visualize the proteins (Figure 2c).
Figure 2a showed that AB&CR 9 efficiently labeled many proteins in the lysate while 10 did
not. The in-gel fluorescence pattern for 11 suggested the labeling of many of the proteins seen
with 9, along with additional background proteins. Significantly, the rhodamine-based probe
used for 9- and 10-modified reactions was different from that used for 11-modified reaction.
The alkyne CR moieties in 9 and 10 required the use of the azide probe 39 for the Cu(I)-
mediated cycloaddition step while the azide CR group in 11 required the alkyne-based probe
40. Cravatt and co-workers have previously reported higher levels of background protein
adduction with alkyne probes compared with their azide counterparts.53 This observation was
consistent with the gel patterns observed for 11 versus 9 and 10 (Figure 2a) that showed more
proteins modified by the probe 40 compared with probe 39 under Cu(I)-mediated cycloaddition
conditions. Similarly, we observed more labeled proteins with 40 compared with 39 in the
absence of the AB&CR agent (Figure 2a, no drug control lanes).
Analysis of the (R)-9- and (S)-9-modified lysate gel patterns showed that some proteins were
more extensively modified by (R)-9 than (S)-9 (Figure 2a, see bands labeled by arrow and
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asterisk). One of these bands appeared to be ~62-kDa (arrow), the approximate molecular
weight of CRMP2.54 To confirm that the ~62-kDa band contained CRMP2, we performed a
western blot analysis using an anti-CRMP2 antibody and observed prominent bands consistent
with full-length and truncated forms of CRMP254 (Figure 2b). In addition to the ~62-kDa band,
we observed another protein band (Figure 2a) with stronger intensity for the (R)-9 lane than
for (S)-9 (Figure 2a, see band labeled by asterisk). The identity of this protein(s) is currently
under investigation.
We recognized that both the increased fluorescence of the ~62 kDa band for the (R)-9 treated
lysate compared with the (S)-9 reaction, and the identification of CRMP2 by western blot
analysis do not demonstrate, by themselves, the preferential modification of CRMP2 by
(R)-9. We suspect that the ~62 kDa band consists of several proteins, and thus the observed
fluorescence pattern may be due to a protein(s) other than CRMP2. Accordingly, additional
studies were conducted to verify the selective modification of CRMP2 by (R)-9. First, the
(R)-9 lysate adduction was repeated. The modified lysate was treated with biotinyl CR probe
35 using Cu(I)-mediated cycloaddition conditions. Substitution of probe 35 for 39 permits the
selective isolation of the (R)-9 captured proteins from the lysate. The biotinylated proteins were
captured with streptavidin beads, the beads stringently washed to remove background proteins
adsorbed on the resin, and then the protein adducts released with SDS treatment. SDS-PAGE
electrophoresis showed bands at ~62 kDa upon Coomassie blue staining. The 62 kDa band
was excised, trypsinized, and analyzed by mass spectrometry (MS). Analysis of the tryptic
fragments indicated the presence of several proteins (e.g., CRMP2, CRMP1, serum albumin)
whose molecular weights were consistent with their electrophoretic mobility. The protein with
the most number of identified fragments in the (R)-9 treated reaction was CRMP2 (17 peptides
including 11 peptides unique to CRMP2 and 6 peptides common to other CRMP proteins, 45%
coverage), followed by CRMP1 (6 peptides including 4 peptides unique to CRMP1 and 2
peptides common to other CRMP proteins, 17% coverage), and serum albumin (4 peptides,
10% coverage), indicating that CRMP2 was a likely major constituent in the ~62 kDa band.
Correspondingly, CRMP2 and other proteins were not observed in ~62 kDa band in the no
drug control reaction. We made a quantitative comparison of the 62 kDa trypsin digests using
differential stable isotope labeling (isobaric tag for relative and absolute quantitation
(iTRAQ)).55 The trypsin digests from the (R)-9, (S)-9, the no drug control reaction, and iTRAQ
buffer alone were each separately treated with distinct iTRAQ isotope labels, the samples
combined, and then analyzed by LC-MS/MS (Supplementary Table S1 in the Supporting
Information). There was no difference in observed iTRAQ ratio between fragments unique to
CRMP2 and those common to other CRMP proteins. The peptide fragments showed, on
average, an ~1.3:1 increase in the relative amounts of each tryptic fragment from the (R)-9
treated sample compared with (S)-9, after normalization to the tubulin fragments, based on the
assumption of no stereochemical preference for lacosamide binding to tubulin. Minor amounts
(<6% compared with the (R)-9 sample) of CRMP2 fragments were observed in the no drug
sample. Analysis of the CRMP1 fragments also showed a 1.3:1 increase in the (R)-9 reaction
compared with the (S)-9 reaction. This differential amount in tryptic fragment abundances was
in agreement with the observed ratio for the fluorescence intensities of the ~62 kDa band in
the (R)-9 reaction versus the (S)-9 experiment (Figure 2a), substantiating the identification of
CRMP1 and CRMP2 as the relevant components of the gel bands from which they were
derived. Finally, we overexpressed CRMP2 as a glutathione-S-transferase (GST)-fusion
protein.56 Attachment of the GST-tag permitted protein purification and increased the size of
the CRMP2 protein by ~25 kDa. The purified recombinant GST-CRMP2 protein (10 μg) was
included in the lysate (50 μL, 2 mg/mL) and the AB&CR adduction reaction repeated with
(R)-9, (S)-9, and no drug. The reaction products were treated with rhodamine azide 39 under
Cu(I)-mediated cycloaddition conditions and then separated by 10% SDS-PAGE (Figure 3).
The electrophoretic mobility of the GST-CRMP2 placed it in a region (~82 kDa) that was
relatively free of other soluble lysate proteins. We observed an approximate 1.5-fold increase
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in fluorescent intensity for the (R)-9 modified GST-CRMP2 protein compared with the
corresponding (S)-9 modified recombinant protein (double arrowhead, Figure 3a). By
comparison, the (R)-9-modified endogenous 62-kDa band was approximately 1.8-fold more
intense than the corresponding (S)-9-modified band (arrow, Figure 3a). Western blot analysis
of the ~82 kDa band was in agreement with the presence of CRMP2 and GST (Figure 3b).
Collectively, these studies show that CRMP2 is preferentially modified in the lysate by
lacosamide AB&CR agent (R)-9, and that (R)-9 leads to higher CRMP2 adduction levels than
the corresponding (S)-9 derivative.
Discussion
A robust strategy is advanced for the discovery of proteins that interact (bind) with small-
molecular-weight ligands (drugs) that explicate function. Our target discovery approach could
be general. As a test case, we have searched for the central nervous system (CNS) binding
partners for (R)-2, a therapeutic agent recently approved for the treatment of partial-onset
seizures.19 Whole animal pharmacological studies indicated that (R)-2 function is unique.20
Our strategy requires the installation of AB and CR units within the drug molecule (Scheme
1). The AB group in 3 covalently modifies the drug target to give 6 rendering permanently a
reversible binding interaction. The CR moiety in 3 is a biologically inert group that specifically
reacts with the bioorthogonal probe 7 designed to either detect or isolate the modified protein
adduct. Specific criteria have been established for the designed AB&CR units. These
requirements are stringent and have been adopted to minimize false positive results. In this
study, we sought lacosamide AB&CR agents that exhibited potent anticonvulsant activity in
rodent models for epilepsy and where the pharmacological activity principally resided in the
enantiomer corresponding to D-serine, similar to that seen for (R)-2. This stereochemical
selectivity for (R)-2 function and related 1s is a distinguishing feature for this class of
compounds,11-13,15,18 and we now show that this enantiospecificity may extend to receptor
tagging as well.
An efficient synthesis was devised to permit the preparation of enantiomerically pure samples
of the AB&CR agents 9–11 and the corresponding AB 27 and 31, and CR 28–30 compounds
(Scheme 1, Schemes S1-S3 in the Supporting Information). Key to our route was the
BF3•Et2O catalyzed ring opening of aziridine 16.44 We found this method versatile, and it
reliably gave optically pure 2-alkoxypropionamide derivatives. The isothiocyanate moiety was
chosen as the AB moiety in 9–11 because of its relative stability in aqueous solutions and its
reactivity with amines and thiols.27 We installed this group from the corresponding amine in
the final step of the synthesis to minimize product loss. For amines 23 and 26, we used di(2-
pyridyl) thionocarbonate,47a and for amine 25 we employed 1,1′-thiocarbonyldiimidazole
47b for this step. We further tested the reactivity of the different AB and CR groups to validate
their use in our proteomic target search (Figure 1).
An important design component for our AB&CR agents is the use of small AB and CR units
in order to minimize possible adverse interactions that could either prevent or alter target
binding. In the case of the C(2) site in (R)-2, for example, we demonstrated that progressive
size increases of the oxygen substituent led to a steady loss in seizure protection in the MES
test (mice, ip).57 A similar structure-activity relationship has been found for the 4′ benzyl
position in (R)-2 derivatives.58 Thus, in (R)-9, we incorporated an isothiocyanate group at the
4′ N-benzyl site for the AB moiety and a propargyl unit at C(2) alkoxy site for the CR moiety.
We found that (R)-9 exhibited notable anticonvulsant activity in mice (ip) (MES ED50 = 45
mg/kg) while the corresponding (S)-9 did not (MES ED50 = >300 mg/kg). The anticonvulsant
activities of the corresponding AB (R)-31 (MES ED50 = 24 mg/kg)43a and CR (R)-28 (MES
ED50 = 16 mg/kg) derivatives exceeded that of the AB&CR agent (R)-9 (MES ED50 = 45 mg/
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kg). The loss of activity observed for (R)-9 is consistent with the cumulative adverse effects
that may have occurred when two groups were appended to the lacosamide framework. We
observed only modest MES seizure protection for AB&CR agent (R)-11 (MES ED50 = 100-300
mg/kg). Moreover, the animal behavioral studies did not differentiate the activities of (R)-11
and its stereoisomer (S)-11. The 6 Hz psychomotor seizure test49 for (R)-30 (mice, ip; 32 mA)
provided evidence to support the use of the 2-azidoethoxy group in this lacosamide AB&CR
agent. The absence of detectable anticonvulsant activity of (R)-27 in mice (>300 mg/kg) in the
MES-seizure test (Table 1) discouraged our preparation and evaluation of the structural isomer
of (R)-11 where the positions of the isothiocyanate and azide moieties are reversed.
Collectively, the whole animal pharmacological data showed that incorporating small AB and
CR units at either the 4′ N-benzyl site or the C(2)-alkoxy position did not markedly perturb
anticonvulsant function and likely did not impede binding to the drug’s cognate receptors. Our
data demonstrated that the seizure protection provided by (R)-9 and (S)-9 mirrored that of
(R)-2 and (S)-2, respectively. Correspondingly, the whole animal pharmacological data for
10 and 11 provided neither support nor evidence against their use for in vitro proteomic
searches. Placement of either an isothiocyanate or azido group at the C(2) aliphatic site may
diminish their activity, in part, presumably by preventing these compounds from reaching the
CNS due to chemical, transport, efflux, and metabolic processes. We chose to interrogate the
mouse brain lysates with all three AB&CR agents (9–11) to gain further information about the
suitability of different AB and CR units for receptor identification, with the understanding that
only animal pharmacological data supported the use of 9.
We first chose to examine the soluble proteome from Charles River male ICR mouse brains.
Comparison of AB&CR agents (R)- and (S)-9–11 showed that (R)-9 and (S)-9 provided the
cleanest in-gel fluorescent patterns while still showing appreciable protein labeling (Figure
2a). This is particularly apparent when the lanes for 9 are compared with that for 11. These
sets of agents contain the same AB unit (4′-isothiocyanate N-benzyl moiety) but have different
CR moieties. Consistent with results reported in the literature, we observed that the number of
proteins modified by using alkyne-based probe 40 were considerably higher than with azide-
based probe 39. We have attributed this, in part, to non-specific lysate modification by the
rhodamine alkyne 40 probe.53 This unwanted reaction complicates receptor identification.
When the protein band pattern for lacosamide AB&CR agent 10 was compared with that for
9, we observed a marked decrease in the extent of protein modification. Compounds 9 and
10 can be considered functional isomers where the structural positions of the AB and CR units
have been reversed. Together, our findings indicate that AB&CR agent 9 may be best suited
for lacosamide target identification.
This study showed that CRMP2 was preferentially modified in the lysate by lacosamide
AB&CR agent (R)-9, and that (R)-9 leads to higher CRMP2 adduction levels than the
corresponding reaction with the (S)-9 derivative. Interrogation of the mouse brain soluble lysate
is complicated by the complexity of the proteome. Thus, several findings were used to validate
CRMP2 labeling. First, western blot analysis verified the presence of CRMP2 in the ~62 kDa
band after lysate modification by (R)-9 and treatment with 39 (Figure 2b). Second, MS analysis
of the trypsin digest of the modified proteins in the ~62 kDa band indicated that CRMP2 was
among the most abundant proteins present in this gel slice. Third, the enhanced adduction by
(R)-9 compared with (S)-9 was confirmed using iTRAQ analysis of the tryptic fragments from
the ~62 kDa band. A modest increase (1.3-fold) in the abundance of CRMP2 fragments was
observed in the (R)-9 adduction experiment compared to (S)-9 reaction when compared to an
internal protein (tubulin alpha chain) (Table S1 in the Supporting Information). The increased
(R)-9 adduction levels are important since whole animal pharmacological studies have
demonstrated that the principal anticonvulsant activity for 2 resided in the (R)-stereoisomer.
Finally, we overexpressed GST-CRMP2 and then added a small amount of the fusion protein
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to the mouse lysate. Repetition of the 9 adduction experiments followed by Cu(I)-mediated
cycloaddition with probe 39 and SDS-PAGE showed increased fluorescent levels (1.5–1.8-
fold) for both the exogenous ~82 kDa and the endogenous ~62 kDa bands in the (R)-9 reaction
compared with the (S)-9 experiment (Figure 3a).
The relative ratios of (R)-9 versus (S)-9 modification of CRMP2 proteins (1.3–1.8-fold) were
modest compared with the observed MES ED50 values for (R)-2 and (S)-2 in this seizure model
in mice (>22-fold).18 Several factors likely contributed to this finding. First, the MES ED50
values for (R)-9 and (S)-9 in rodents represent a composite value that encompasses numerous
pharmacological factors that include binding to target(s), metabolism, transport, efflux, and
nonspecific binding to abundant cellular proteins. Therefore, the in vitro modification data is
not likely to fully recapitulate the in vivo pharmacological results. Second, different (R)-2
targets likely display different stereochemical preferences for the 9 enantiomers, and this
stereochemical preference may be further influenced by the AB and CR groups that are
incorporated within the lacosamide framework to facilitate in vitro analysis. Finally, we expect
that the conditions of adduction such as drug and target concentration, temperature, and time
will affect the levels of (R)-9 and (S)-9 CRMP2 adduction. For our experiments, we used
relatively high amounts of 9 and moderate reaction conditions to provide substantial protein
adduction levels.
Our results support a report by Beyreuther and coworkers that CRMP2 may interact with
(R)-2.21 In their study, (R)-2-like derivatives (precise structures not disclosed) that contained
an appended isothiocyanate group and a biotin moiety were prepared and then reacted with
mouse brain lysates. Subsequent treatment of the modified lysate with streptavidin removed
the biotinylated tagged proteins. Differentiating Beyreuther and colleagues’ study from ours
was their use of significantly larger (R)-2-type agents and the absence of whole animal
pharmacological data to support their use. Knowing these collective findings, detailed studies
are warranted to determine the site of (R)-3 CRMP2 adduction and to validate this protein as
an (R)-2 target.
We observed other possible (R)-2 binding target(s) (Figure 2a, asterisk band). The identity of
this band is under investigation. Only mouse soluble brain proteome was used in this study.
Future studies will examine the membrane-bound fraction. In this regard, (R)-2 has been
reported to selectively enhance the slow inactivation of voltage-gated sodium channels.22 The
combined use of our AB&CR (R)-3 agents, enzymatic digestion, and MS of the protein
fragments may help reveal the site(s) of drug binding.
Conclusions
We advance a strategy to identify molecular targets for ligands (e.g., drugs) whose binding to
their cognate receptors is modest and where moderate-to-extensive structural change abolishes
target binding. Our method requires the installation of AB and CR units within the ligand where
the AB group covalently modifies the target and the CR group is used to either identify or
isolate the ligand-modified receptor. Strict guidelines for the use of the AB&CR strategy have
been established to increase the success of this method and to minimize the isolation of false
positive sites. Among these guidelines are that the AB and CR groups must conform to the
SAR for the ligand and that the pharmacological profile for the AB&CR agent mirror that of
the ligand. Using this approach we interrogated the mice brain soluble proteome for (R)-2
binding sites. We identified several potential drug targets including CRMP2, a protein
previously suggested to interact with (R)-2. Further studies will be needed to validate these
targets and to identify the sites of drug interaction.
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Melting points were determined in open capillary tubes using a Thomas-Hoover melting point
apparatus and are uncorrected. Infrared spectra (IR) were run on an ATI Mattson Genesis FT-
IR spectrometer. Absorption values are expressed in wavenumbers (cm−1). Optical rotations
were obtained on a Jasco P-1030 polarimeter at the sodium D line (589 nm) using a 1 dm path
length cell. NMR spectra were obtained at 300 MHz (1H) and 75 MHz (13C) using TMS as an
internal standard. Chemical shifts (δ) are reported in parts per million (ppm) from
tetramethylsilane. Low-resolution mass spectra were obtained with a BioToF-II-Bruker
Daltonics spectrometer by Drs. Matt Crowe and S. Habibi at the University of North Carolina
Department of Chemistry. The high-resolution mass spectrum was performed on a Bruker
Apex-Q 12 Telsa FTICR spectrometer by Drs. Matt Crowe and S. Habibi. Microanalyses were
performed by Atlantic Microlab, Inc. (Norcross, GA). Reactions were monitored by analytical
thin-layer chromatography (TLC) plates (Aldrich, Cat # Z12272-6) and analyzed with 254 nm
light. The reaction mixtures were purified by MPLC (CombiFlash Rf) with self-packed
columns (silica gel from Dynamic Adsorbents Inc., Cat # 02826-25) or by flash column
chromatography using silica gel (Dynamic Adsorbents Inc., Cat # 02826-25). All chemicals
and solvents were reagent grade and used as obtained from commercial sources without further
purification. THF was distilled from blue sodium benzophenone ketyl. Yields reported are for
purified products and were not optimized. All compounds were checked by TLC, 1H and 13C
NMR, MS, and elemental analyses. The analytical results are within +0.40% of the theoretical
value. The TLC, NMR and the analytical data confirmed the purity of the products was ≥95%.
General procedure for the aziridine ring opening of (R)/(S)-16 with alcohols. Method A
To a cooled CH2Cl2 solution (ice bath) containing the N-acetylaziridine methyl ester (R)/
(S)-16 ([C] ~ 0.5–1 M) and the appropriate alcohol (1–3 eq.) was added BF3•Et2O (0.1–1 equiv)
dropwise while stirring. After addition, the mixture was warmed to room temperature and
stirred (90 min—2 h), and then an equal volume of saturated aqueous NaHCO3 was added.
The reaction was vigorously stirred (15 min) and the organic layer separated. The aqueous
layer was extracted with CH2Cl2 until no product could be detected (TLC analysis) and then
all the organic layers were combined, dried (Na2SO4), and concentrated in vacuo to yield a
residue that was purified by flash column chromatography.
General procedure for the ester hydrolysis of (R)/(S)-17 or (R)/(S)-18 with LiOH. Method B
To a THF solution of methyl ester (2 volumes, [C] ~ 0.1 M) was added an aqueous LiOH (1
equiv) solution (1 volume). The reaction was stirred at room temperature (90 min—12 h), after
which time the aqueous layer was washed with Et2O (2 volumes). The aqueous layer was
acidified (pH ~ 1) by the dropwise addition of aqueous concentrated HCl at 0 °C, saturated
with NaCl, and extracted with EtOAc until no further product was detected (TLC analysis).
The combined organic layers were combined, dried (Na2SO4), and evaporated to an oily residue
that was used directly for the next step, or recrystallized when needed from EtOAc and hexanes
to provide an analytical sample.
General procedure for the mixed anhydride coupling reaction. Method C
To a cooled THF solution (−78 °C, dry ice acetone bath) of acid (R)/(S)-19 ([C] ~ 0.1 M) were
successively added NMM (1.0–1.1 equiv), stirred for 2 min, IBCF (1.0–1.2 equiv), stirred for
5 min, and then the desired benzylamine (1.0–1.2 equiv). Upon addition the reaction mixture
was allowed to warm to room temperature and further stirred (2–3 h). The salts were filtered
and rinsed with THF and the filtrate was concentrated in vacuo. The residue obtained was
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purified by flash chromatography, followed by recrystallization from EtOAc and hexanes when
necessary.
General procedure for the DMTMM amide coupling reaction. Method D
To a THF solution of acid (R)/(S)-20 ([C] ~ 0.1 M) at room temperature was added the desired
benzylamine (1.2 equiv). The solution was stirred (5–10 min) until the benzylammonium
carboxylate precipitated. While stirring, DMTMM (1.2 equiv) was added all at once, and the
resulting suspension was stirred at room temperature (3–12 h). In those cases where a salt did
not precipitate, DMTMM was added after 15 min to the solution. The salts were removed by
filtration, washed with THF, and the solvent was removed in vacuo. The residue obtained was
purified by flash column chromatography to afford the benzylamide, and then recrystallized
from EtOAc and hexanes.
(R)-Methyl 2-Acetamido-3-(prop-2-ynyloxy)propionate ((R)-17)
Utilizing Method A, (R)-methyl 1-acetylaziridine-2-carboxylate44 ((R)-16) (1.50 g, 10.49
mmol), propargyl alcohol (0.92 mL, 15.74 mmol) and BF3•Et2O (1.39 mL, 11.01 mmol) gave
1.43 g (68%) of (R)-17 as a white solid after recrystallization with cold hexanes: mp 58.5–59.5
°C; [α]25D −64.6° (c 1.0, CHCl3); Rf = 0.35 (3/1 EtOAc/hexanes); IR (nujol mull) 3301, 2919,
2114, 1750, 1639, 1542, 1457 cm−1; 1H NMR (CDCl3) δ 2.06 (s, CH3C(O)), 2.46 (t, J = 2.3
Hz, CH2CCH), 3.78 (s, OCH3), 3.79 (dd, J = 3.3, 9.6 Hz, CHH’OCH2), 3.98 (dd, J = 2.9, 9.6
Hz, CHH’OCH2), 4.09–4.21 (m, OCH2C), 4.77–4.82 (m, CH), 6.33–6.35 (br d, J = 7.2 Hz,
NHCH); 13C NMR (CDCl3) δ 23.3 (CH3C(O)), 52.6 (CH), 52.8 (OCH3), 58.7 (CH2CCH),
69.6 (CH2OCH2), 75.3 (CH2CCH), 79.0 (CH2CCH), 170.1, 170.8 (2 C(O)); Mr (+ESI)
200.0916 [M+H]+ (calcd for C9H13NO4H+ 200.0923 [M+H]+). Anal. (C9H13NO4): C, H, N.
(S)-Methyl 2-Acetamido-3-(prop-2-ynyloxy)propionate ((S)-17)
Utilizing the preceding procedure and using (S)-1644 (1.50 g, 10.49 mmol), propargyl alcohol
(0.92 mL, 15.74 mmol) and BF3•Et2O (1.39 mL, 11.01 mmol) gave 1.32 g (63%) of (S)-17 as
a white solid: mp 59.0–59.5 °C; [α]25D +65.3° (c 1.0, CHCl3); Rf = 0.35 (3/1 EtOAc/hexanes);
IR (nujol mull) 3296, 2924, 2116, 1740, 1641, 1543, 1457 cm−1; 1H NMR (CDCl3) δ 2.06 (s,
CH3C(O)), 2.46 (t, J = 2.4 Hz, CH2CCH), 3.78 (s, OCH3), 3.79 (dd, J = 3.2, 9.4 Hz,
CHH’OCH2), 3.98 (dd, J = 3.0, 9.4 Hz, CHH’OCH2), 4.12 (1/2HH’q, J = 2.4, 16.2 Hz,
OCHH’C), 4.18 (1/2HH’q, J = 2.4, 16.2 Hz, OCHH’C), 4.77–4.82 (m, CH), 6.32–6.34 (br d,
J = 7.2, NHCH); 13C NMR (CDCl3) δ 23.3 (CH3C(O)), 52.6 (CH), 52.8 (OCH3), 58.7
(CH2CCH), 69.6 (CH2OCH2), 75.3 (CH2CCH), 79.0 (CH2CCH), 170.1, 170.7 (2 C(O)); Mr
(+ESI) 200.0917 [M+H]+ (calcd for C9H13NO4H+ 200.0923 [M+H]+)). Anal. (C9H13NO4) C,
H, N.
(R)-2-Acetamido-3-(prop-2-ynyloxy)propionic Acid ((R)-19)
Utilizing Method B, (R)-17 (1.00 g, 5.03 mmol), LiOH (0.6 M, 8.4 mL, 5.03 mmol) gave 0.87
g of (R)-19 (94%) as a yellow oil: Rf = 0.35 (15/5/1 EtOAc/hexanes/AcOH); IR (nujol mull)
3264, 2924, 2120, 1726, 1642, 1548, 1459 cm−1; 1H NMR (CD3OD) δ 2.01 (s, CH3C(O)),
2.88 (t, J = 2.6 Hz, CH2CCH), 3.77 (dd, J = 3.6, 9.7 Hz, CHH’OCH2), 3.92 (dd, J = 5.0, 9.7
Hz, CHH’OCH2), 4.18 (d, J = 2.6 Hz, OCH2C), 4.61–4.64 (m, CH); 13C NMR (CD3OD) δ
22.5 (CH3C(O)), 54.1 (CH), 59.3 (CH2CCH), 70.4 (CH2OCH2), 76.5 (CH2CCH), 80.2
(CH2CCH), 173.1, 173.5 (2 C(O)); Mr (+ESI) 186.0761 [M+H]+ (calcd for C8H11NO4H+
186.0766 [M+H]+). Anal. (C8H11NO4•0.14H2O): C, H, N.
(S)-2-Acetamido-3-(prop-2-ynyloxy)propionic Acid ((S)-19)
Utilizing the preceding procedure and using (S)-17 (1.00 g, 5.03 mmol) and LiOH (0.6 M, 8.4
mL, 5.03 mmol) gave 0.86 g (93%) of (S)-19 as a yellow oil: Rf = 0.35 (15/5/1 EtOAc/hexanes/
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AcOH); IR (nujol mull) 3270, 2924, 2120, 1729, 1641, 1547, 1459 cm−1; 1H NMR (DMSO-
d6) δ 1.87 (s, CH3C(O)), 3.48 (t, J = 2.4 Hz, CH2CCH), 3.62 (dd, J = 4.1, 9.6 Hz,
CHH’OCH2), 3.74 (dd, J = 2.4, 9.6 Hz, CHH’OCH2), 4.16 (d, J = 2.4 Hz, OCH2C), 4.41–4.47
(m, CH), 8.21–8.23 (d, J = 8.4 Hz, NHCH); 13C NMR (DMSO-d6) δ 22.4 (CH3C(O)), 52.1
(CH), 57.8 (CH2CCH), 69.2 (CH2OCH2), 77.6 (CH2CCH), 79.9 (CH2CCH), 169.6, 171.5 (2
C(O)); Mr (+ESI) 186.0760 [M+H]+ (calcd for C8H11NO4H+ 186.0766 [M+H]+). Anal.
(C8H11NO4•0.25H2O) C, H, N.
(R)-Methyl 2-Acetamido-3-(2-azidoethoxy)propionate ((R)-18)
Using Method A, compound (R)-1644 (2.35 g, 16.4 mmol), 2-azidoethanol (4.5 mL, 65.6 mmol)
and BF3•Et2O (1 mL, 8.2 mmol) gave 1.56 g (41%) of (R)-18 after purification: [α]25D +49.1°
(c 1.0; EtOAc); Rf = 0.47 (EtOAc); IR (neat) 3302, 2948, 2107, 1746, 1668, 1534, 1443
cm−1; 1H NMR (CDCl3) δ 2.06 (s, CH3C(O)NH), 3.23–3.42 (m, CH2N3), 3.31–3.64 (m,
OCH2CH2N3, CHCHH’OCH2), 3.78 (s, OCH3), 3.96 (dd, J = 3.0, 9.1 Hz CHCHH’OCH2),
4.76–4.81 (m, CHCH2O), 6.30–6.41 (br d, CH C(O)NH); 13 3 C NMR (CDCl3) δ 23.2
(CH3C(O)), 50.0 (OCH2CH2N3), 52.6 (OCH3 or CHCH2O), 52.8 (CHCH2O or OCH3), 70.9
(CHCH2O or OCH2CH2N3), 71.1 (OCH2CH2N3 or CHCH2O), 170.1, 170.6 (C(O)OCH3,
CH3C(O)NH); Mr (+ESI) 253.0906 [M+Na]+ (calcd for C8H14N4O4Na+ 253.0913 [M
+Na]+).
(S)-Methyl 2-Acetamido-3-(2-azidoethoxy)propionate ((S)-18)
Utilizing the preceding procedure, and using (S)-1644 (3.30 g, 23 mmol), 2-azidoethanol (6.3
mL, 92 mmol), and BF3•Et2O (1.4 mL, 11.5 mmol) in CH2Cl2 (115 mL) gave 1.67 g (31%)
of a colorless residue: [α]25D −48.0° (c 1.0; EtOAc); Rf = 0.47 (EtOAc); IR (neat) 3302, 2948,
2107, 1746, 1667, 1534, 1443 cm−1; 1H NMR (CDCl3) δ 2.06 (s, CH3C(O)NH), 3.23–3.42
(m, CH2N3), 3.31–3.64 (m, OCH2CH2N3, CHCHH’OCH2), 3.78 (s, OCH3), 3.96 (dd, J = 3.0,
9.1 Hz CHCHH’OCH2), 4.76–4.81 (m, CHCH2O), 6.30–6.41 (br d, CH3C(O)NH); 13C NMR
(CDCl3) δ 23.3 (CH3C(O)), 50.1 (OCH2CH2N3), 52.7 (OCH3 or CHCH2O), 52.9 (CHCH2O
or OCH3), 71.0 (CHCH2O or OCH2CH2N3), 71.2 (OCH2CH2N3 or CHCH2O), 170.2, 170.7
(CH3C(O)NH and C(O)OCH3); Mr (+ESI) 253.0906 [M+Na]+ (calcd for C8H14N4O4Na+
253.0913 [M+Na]+).
(R)-2-Acetamido-3-(2-azidoethoxy)propionic Acid ((R)-20)
Utilizing Method B, and using compound (R)-18 (1.56 g, 6.78 mmol) in THF (60 mL) and
LiOH (195 mg, 8.14 mmol) in H2O (30 mL) gave 750 mg (51%) of (R)-20 as a white solid.
An analytical sample was obtained by recrystallization from EtOAc and hexanes: mp 99–100
°C; [α]25D −12.6° (c 1.8; MeOH); Rf = 0.21 (1/9 MeOH/CHCl3); IR (nujol mull) 3356, 2119,
1735, 1624, 1547 cm−1; 1H NMR (CDCl3) δ 2.07 (s, CH3C(O)NH), 3.23– 3.42 (m, CH2N3),
3.60–3.80 (m, OCH2CH2N3, CHCHH’O), 4.01 (dd, J = 3.0, 9.1 Hz, CHCHH’O), 4.76–4.80
(m, CHCH2O), 6.00–7.00 (br, CO2H), 6.48 (d, J = 7.5 Hz, CH3C(O)NH), no signal could be
detected for the COOH proton; 13C NMR (DMSO-d6)  22.3 (CH3C(O)), 49.9
(OCH2CH2N3), 52.2 (CHCH2O), 69.4 (CHCH2O or OCH2CH2N3), 70.1 (OCH2CH2N3 or
CHCH2O), 169.4 (CH3C(O)NH or C(O)OH), 171.5 (C(O)OH or CH3C(O)NH); Mr (+ESI)
239.0750 [M+Na]+ (calcd for C7H12N4O4Na+ 239.0756, [M+Na]+). Anal.
(C7H12N4O4•0.07EtOAc): C, H, N.
(S)-2-Acetamido-3-(2-azidoethoxy)propionic Acid ((S)-20)
Utilizing the preceding procedure and using (S)-18 (1.67 g, 7.26 mmol) in THF (60 mL), and
LiOH (209 mg, 8.71 mmol) in H2O (30 mL) gave 862 mg (55%) of (S)-20 as a white solid
upon work-up and evaporation. An analytical sample was obtained by recrystallization from
EtOAc and hexanes: mp 99–100 °C; [α]25D +12.4° (c 1.3; MeOH); Rf = 0.21 (1/9 MeOH/
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CHCl3); IR (nujol mull) 3356, 2119, 1735, 1624, 1547 cm−1; 1H NMR (DMSO-d6) δ 1.86 (s,
CH3C(O)NH), 3.30–3.45 (m, CH2N3), 3.50–3.78 (m, OCH2CH2N3, CHCH2OCH2), 4.39–
4.48 (m, CHCH2O), 8.13 (d, J = 8.1 Hz, CH3C(O)NH), no signal could be detected for the
COOH proton; 13C NMR (DMSO-d6)  22.3 (CH3C(O)), 49.9 (OCH2CH2N3), 52.2
(CHCH2O), 69.4 (CHCH2O or OCH2CH2N3), 70.1 (OCH2CH2N3 or CHCH2O), 169.4
(CH3C(O)NH or C(O)OH), 171.5 (C(O)OH or CH3C(O)NH); Mr (+ESI) 239.0750 [M
+Na]+ (calcd for C7H12N4O4Na+ 239.0756 [M+Na]+). Anal. (C7H12N4O4•0.07EtOAc): C, H,
N.
(R)-N-(4-Amino)benzyl 2-Acetamido-3-(prop-2-ynyloxy)propionamide ((R)-23)
Utilizing Method C, (R)-19 (0.25 g, 1.37 mmol), NMM (0.23 mL, 2.06 mmol), IBCF (0.23
mL, 1.73 mmol), and 4-aminobenzylamine (22) (0.21 mL, 1.85 mmol) gave 0.24 g (61%) of
(R)-23 as a light yellow solid: mp 97.5–98.5 °C; [α]25D +4.2° (c 1.0, MeOH); Rf = 0.40 (1/9
MeOH/CHCl3); IR (nujol mull) 3279, 2930, 2111, 1628, 1536, 1459 cm−1; 1H NMR
(CDCl3) δ 2.00 (s, CH3C(O)), 2.44 (t, J = 2.4 Hz, CH2CCH), 3.62 (dd, J = 6.9, 9.3 Hz,
CHH’OCH2), 3.56–3.72 (br m, NH2), 3.88 (dd, J = 4.1, 9.3 Hz, CHH’OCH2), 4.12
(1/2HH’q, J = 2.4, 15.9 Hz, OCHH’C), 4.19 (1/2HH’q, J = 2.4, 15.9 Hz, OCHH’C), 4.32 (d,
J = 5.7 Hz, CH2Ar), 4.54–4.60 (m, CH), 6.55–6.58 (br d, J = 7.2 Hz, NHCH), 6.60–6.65 (m,
2 ArH), 6.65-6.71 (br m, NHCH2), 7.03-7.06 (m, 2 ArH); 13C NMR (CDCl3) δ 23.4 (CH3C
(O)), 43.5 (CH2Ph), 52.7 (CH), 58.8 (CH2CCH), 69.4 (CH2OCH2), 75.5 (CH2CCH), 79.1
(CH2CCH), 115.4, 127.7, 129.1, 146.1 (ArC), 169.6, 170.5 (2 C(O)); Mr (+ESI) 290.1500 [M
+H]+ (calcd for C15H19N3O3H+ 290.1505 [M+H]+). Anal. (C15H19N3O3): C, H, N.
(S)-N-(4-Amino)benzyl 2-Acetamido-3-(prop-2-ynyloxy)propionamide ((S)-23)
Utilizing the preceding procedure and using (S)-19 (0.25 g, 1.37 mmol), NMM (0.20 mL, 1.78
mmol), IBCF (0.19 mL, 1.44 mmol), and 22 (0.16 mL, 1.44 mmol) gave 0.30 g (77%) of
(S)-23 as a light yellow solid: mp 97.0–98.0 °C; [α]25D −4.1° (c 1.0, MeOH); Rf = 0.40 (1/9
MeOH/CHCl3); IR (nujol mull) 3282, 2924, 2112, 1630, 15372, 1458 cm−1; 1H NMR
(CDCl3) δ 2.03 (s, CH3C(O)), 2.45 (t, J = 2.4 Hz, CH2CCH), 3.62 (dd, J = 7.1, 9.1 Hz,
CHH’OCH2), 3.62–3.74 (br m, NH2), 3.92 (dd, J = 4.2, 9.1 Hz, CHH’OCH2), 4.14
(1/2HH’q, J = 2.4, 15.9 Hz, OCHH’C), 4.22 (1/2HH’q, J = 2.4, 15.9 Hz, OCHH’C), 4.35 (d,
J = 6.0, CH2Ar), 4.53–4.59 (m, CH), 6.42–6.44 (br d, J = 6.3 Hz, NHCH), 6.48–6.56 (br m,
NHCH2), 6.62–6.67 (m, 2 ArH), 7.03–7.08 (m, 2 ArH); 13C NMR (CDCl3) δ 23.6 (CH3C(O)),
43.8 (CH2Ph), 52.9 (CH), 59.0 (CH2CCH), 69.7 (CH2OCH2), 75.7 (CH2CCH), 79.4
(CH2CCH), 115.6, 128.0, 129.4, 146.3 (C6H4), 169.9, 170.7 (2 C(O)); Mr (+ESI) 290.1499
[M+H]+ (calcd for C15H19N3O3H+ 290.1505 [M+H]+). Anal. (C15H19N3O3): C, H, N.
(R)-N-(4-Isothiocyanato)benzyl 2-Acetamido-3-(prop-2-ynyloxy)propionamide ((R)-9)
To a dry THF solution (20 mL) of (R)-23 (0.17 g, 0.60 mmol) was added dropwise a solution
of DPT (0.21 mL, 0.89 mmol) in THF (8 mL). The reaction solution was stirred under Ar at
room temperature (2 h). The solvent was removed in vacuo, and the product was purified by
silica gel column chromatography (1/9 acetone/EtOAc) to give 0.15 g (77%) of (R)-9 as a white
solid: mp 157–159 °C; [α]25D −10.9° (c 1.5, CHCl3); Rf = 0.40 (1/9 acetone/EtOAc); IR (nujol
mull) 3270, 2924, 2084, 1634, 1553, 1459 cm−1; 1H NMR (CDCl3) δ 2.03 (s, CH3C(O)), 2.48
(t, J = 2.5 Hz, CH2CCH), 3.65 (dd, J = 7.1, 9.3 Hz, CHH’OCH2), 3.92 (dd, J = 4.2, 9.3 Hz,
CHH’OCH2), 4.15 (1/2HH’q, J = 2.5, 15.9 Hz, OCHH’C), 4.22 (1/2HH’q, J = 2.5, 15.9 Hz,
OCHH’C), 4.40 (1/2HH’q, J = 5.9, 15.5 Hz, CHH’Ar), 4.49 (1/2HH’q, J = 5.9, 15.5 Hz,
CHH’Ar), 4.60–4.66 (m, CH), 6.52 (br d, J = 6.9 Hz, NHCH), 6.96 (br t, J = 5.9 Hz,
NHCH2), 7.16–7.19 (m, 2 ArH), 7.24–7.27 (m, 2 ArH), addition of excess (R)-(−)-mandelic
acid to a CDCl3 solution of (R)-9 gave only a single signal for the acetyl methyl protons and
the alkyne proton, addition of excess (R)-(−)-mandelic acid to a CDCl3 solution of (R)-9 and
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(S)-9 (1:2 ratio) gave two signals for the acetyl methyl protons (δ 2.019 (R) and 2.033 (S)
(Δppm = 0.014)), and two signals for the alkyne proton (δ 2.424 (S) and 2.462 (R) (Δppm =
0.038)); 13C NMR (CDCl3) δ 23.4 (CH3C(O)), 43.1 (CH2Ph), 52.7 (CH), 58.9 (CH2CCH),
69.3 (CH2OCH2), 75.6 (CH2CCH), 79.0 (CH2CCH), 126.1, 128.8, 130.6 (3 ArC), 135.7
(NCS), 137.5 (1 ArC), 170.0, 170.6 (2 C(O)); Mr (+ESI) 332.1065 [M+H]+ (calcd for
C16H17N3O3SH+ 332.1069 [M+H]+). Anal. (C16H17N3O3S): C, H, N, S.
(S)-N-(4-Isothiocyanato)benzyl 2-Acetamido-3-(prop-2-ynyloxy)propionamide ((S)-9)
Utilizing the preceding procedure, and using (S)-23 (0.30 g, 1.02 mmol), and DPT (0.32 g,
1.38 mmol) gave 0.25 g (75%) of pure (S)-9 as a white solid: mp 157–158 °C; [α]25D +10.6°
(c 1.5, CHCl3); Rf = 0.40 (1/9 MeOH/CHCl3); IR (nujol mull) 3272, 2924, 2084, 1633, 1553,
1459 cm−1; 1H NMR (CDCl3) δ 2.04 (s, CH3C(O)), 2.48 (t, J = 2.5 Hz, CH2CCH), 3.65 (dd,
J = 7.1, 9.2 Hz, CHH’OCH2), 3.94 (dd, J = 4.1, 9.2 Hz, CHH’OCH2), 4.16 (1/2HH’q, J = 2.5,
16.0 Hz, OCHH’C), 4.24 (1/2HH’q, J = 2.5, 16.0 Hz, OCHH’C), 4.42 (1/2HH’q, J = 6.3, 15.5
Hz, CHH’Ar), 4.50 (1/2HH’q, J = 6.3, 15.5 Hz, CHH’Ar), 4.57–4.63 (m, CH), 6.41–6.43 (br
d, J = 6.6 Hz, NHCH), 6.81 (br t, J = 6.3 Hz, NHCH2), 7.17–7.20 (m, 2 ArH), 7.25-7.27 (m,
2 ArH), addition of excess (R)-(−)-mandelic acid to a CDCl3 solution of (S)-9 gave only a
single signal for the acetyl methyl protons and the alkyne proton, addition of excess (R)-(−)-
mandelic acid to a CDCl3 solution of (R)-9 and (S)-9 (1:2 ratio) gave two signals for the acetyl
methyl protons (δ 2.019 (R) and 2.033 (S) (Δppm = 0.014)), and two signals for the alkyne
proton (δ 2.424 (S) and 2.462 (R) (Δppm = 0.038)); 13C NMR (CDCl3) δ 23.3 (CH3C(O)),
43.1 (CH2Ph), 52.7 (CH), 58.8 (CH2CCH), 69.3 (CH2OCH2), 75.6 (CH2CCH), 79.0
(CH2CCH), 126.1, 128.7, 130.5 (3 ArC), 135.7 (NCS), 137.5 (1 ArC), 170.0, 170.7 (2 C(O));
Mr (+ESI) 332.1063 [M+H]+ (calcd for C16H17N3O3SH+ 332.1069 [M+H]+). Anal.
(C16H17N3O3S): C, H, N, S.
(R)-N-(4-Isothiocyanato)benzyl 2-Acetamido-3-(2-azidoethoxy)propionamide ((R)-11)
Utilizing Method D, and using acid (R)-20 (1130 mg, 5.2 mmol), 4-aminobenzylamine (22)
(760 mg, 6.3 mmol), and DMTMM (1730 mg, 6.3 mmol) in THF (100 mL) gave 715 mg (42%)
of a dark brown residue. The residue was directly dissolved in dry acetonitrile (40 mL) and
DITC (90%, 510 mg, 2.57 mmol) was added all at once. The reaction solution was stirred at
room temperature (1 h), the solvent was removed in vacuo, and the residue purified using flash
chromatography (5/95 MeOH/CHCl3) and then recrystallized from EtOAc to yield 502 mg
(27%, 2 steps) of (R)-11 as an off-white solid: mp 142–143 °C; [α]25D −28.6° (c 0.81;
CHCl3); Rf = 0.45 (1/9 acetone/EtOAc); IR (nujol mull) 3276, 2181, 2114, 1631, 1547, 1459,
1374, 1285 cm−1; 1H NMR (CDCl3) δ 2.05 (s, CH3C(O)NH), 3.30–3.50 (m, CH2N3), 3.55
(dd, J = 7.5, 9.3 Hz, CHCHH’OCH2), 3.62–3.80 (m, OCH2CH2N3), 3.95 (dd, J = 4.0, 9.3 Hz,
CHCHH’OCH2), 4.46 (d, J = 6.0 Hz, C(O)NHCH2Ph), 4.54–4.60 (m, CHCH2O), 6.45 (br d,
J = 6.2 Hz, CH3C(O)NH), 6.84–6.92 (br t, C(O)NHCH2Ph), 7.18–7.22 (m, 2 ArH), 7.23–7.29
(m, 2 ArH), addition of excess (R)-(−)-mandelic acid to a CDCl3 solution of (R)-11 gave only
one signal for the acetyl protons, addition of excess (R)-(−)-mandelic acid to a CDCl3 solution
of (S)-11 and (R)-11 (1:2 ratio) gave two signals for the acetyl methyl protons (δ 2.033 (S) and
2.020 (R) (Δppm = 0.013); 13C NMR (CDCl3)  23.2 (CH3C(O)), 41.0 (NHCH2Ph), 50.7
(CH2N3), 52.4 (CHCH2O), 70.0 (OCH2CH2N3 or CHCH2O), 70.3 (CHCH2O or
OCH2CH2N3), 125.9, 128.6, 130.5 (3 ArC), 135.6 (NCS), 137.4 (1 ArC), 169.8, 169.2
(CH3C(O)NH, C(O)NHCH2); Mr (+ESI) 363.1236 [M+H]+ (calcd for C15H18N6O3SH+
363.1239 [M+H]+). Anal. (C15H18N6O3S): C, H, N, S.
(S)-N-(4-Isothiocyanato)benzyl 2-Acetamido-3-(2-azidoethoxy)propionamide ((S)-11)
Utilizing the preceding procedure, and using acid (S)-20 (1.61 g, 7.52 mmol), 22 (1.02 mL,
9.03 mmol) and DMTMM (2.50 g, 9.03 mmol) in anhydrous THF (200 mL) followed by DITC
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(90%, 1.58 g, 7.90 mmol) in acetonitrile (20 mL) gave 706 mg (26%, two steps) of (S)-11 as
an off-white solid after flash chromatography and recrystallization: mp 142–143 °C; [α]25D
+28.5° (c 0.95; CHCl3); Rf = 0.45 (1/9 acetone/EtOAc); IR (nujol mull) 3280, 2177, 2108,
1637, 1548, 1452, 1374, 1293 cm−1; 1H NMR (CDCl3) δ 2.01 (s, CH3C(O)NH), 3.28–3.48
(m, CH2N3), 3.55 (dd, J = 7.2, 9.3 Hz, CHCHH’OCH2), 3.62-3.78 (m, OCH2CH2N3), 3.91
(dd, J = 4.0, 9.3 Hz, CHCHH’OCH2), 4.43 (d, J = 6.0 Hz, C(O)NHCH2Ph), 4.56–4.62 (m,
CHCH2O), 6.56 (br d, J = 6.2 Hz, CH3C(O)NH), 6.84–6.92 (br t, J = 6.0 Hz, C(O)
NHCH2Ph), 7.14–7.20 (m, 2 ArH), 7.22–7.28 (m, 2 ArH), addition of excess (R)-(−)-mandelic
acid to a CDCl3 solution of (S)-11 gave only one signal for the acetyl protons, addition of
excess (R)-(−)-mandelic acid to a CDCl3 solution of (S)-11 and (R)-11 (1:2 ratio) gave two
signals for the acetyl methyl protons (δ 2.033 (S) and 2.020 (R) (Δppm = 0.013); 13C NMR
(CDCl3)  23.3 (CH3C(O)), 43.2 (NHCH2Ph), 50.9 (CH2N3), 52.7 (CHCH2O), 70.3
(OCH2CH2N3 or CHCH2O), 70.4 (CHCH2O or OCH2CH2N3), 126.1, 128.8, 130.6 (3 ArC),
135.8 (NCS), 137.6 (1 ArC), 170.0, 170.7 (CH3C(O)NH, C(O)NHCH2); Mr (+ESI) 363.1241
[M+H]+ (calcd for C15H18N6O3SH+ 363.1239 [M+H]+). Anal. (C15H18N6O3S): C, H, N, S.
(R)-N-(4-Ethynyl)benzyl 2-Acetamido-3-(2-azidoethoxy)propionamide ((R)-24)
Using Method C, (R)-2-acetamido-3-(2-azidoethoxy)propionic acid ((R)-20) (0.31 g, 1.4
mmol), NMM (189 μL, 1.7 mmol), IBCF (228 μL, 1.7 mmol), 4-ethynylbenzylamine (21) (225
mg, 1.7 mmol), and THF (20 mL) gave 0.26 g (55%) of (R)-24 as a white solid: Rf = 0.18
(EtOAc); mp 80–87 °C (dec); [α]25D +4.8° (c 0.5, DMSO); IR (nujol mull) 3282, 2103, 1636,
1548, 1458, 1375, 1303, 1258, 1124, 982, 821, 721 cm−1; 1H NMR (CDCl3) δ 2.03 (s, CH3C
(O)), 3.08 (s, HC≡C), 3.27-3.46 (m, CH2N3), 3.56 (dd, J = 7.2, 9.6 Hz, OCHH’), 3.62–3.77
(m, CH2CH2O), 3.92 (dd, J = 3.6, 9.6 Hz, OCHH’), 4.46 (d, J = 5.7 Hz, CH2N), 4.56–4.62
(m, CH), 6.53 (d, J = 6.9 Hz, NH), 6.88–7.01 (br t, CH2NH), 7.22 (d, J = 8.1 Hz, 2 ArH), 7.45
(d, J = 8.1 Hz, 2 ArH); 13C NMR (CDCl3) δ 23.1 (CH3CO), 43.3 (CH2N), 50.7 (CH2N3), 52.5
(CH), 70.1 (CH2O), 70.3 (CH2O), 77.4 (C≡C), 83.3 (C≡C), 121.3, 127.4, 132.4, 138.7 (4
ArC), 169.8, 170.5 (2 C(O)); Mr (+ESI) 330.1569 [M+H]+ (calcd for C16H19N5O3H+ 330.1566
[M+H]+).
(S)-N-(4-Ethynyl)benzyl 2-Acetamido-3-(2-azidoethoxy)propionamide ((S)-24)
Utilizing the preceding procedure, and using THF (20 mL), (S)-20 (0.31 g, 1.4 mmol), NMM
(189 μL, 1.7 mmol), IBCF (225 μL, 1.7 mmol) and 21 (225 mg, 1.7 mmol) gave 165 mg of a
white solid (35%): Rf = 0.18 (EtOAc); mp 107–109 °C; [α]25D −6.0° (c 0.5, DMSO); IR (nujol
mull) 3274, 2100, 1635, 1548, 1457, 1375, 1301, 1257, 1121, 980, 820, 719 cm−1; 1H NMR
(CDCl3) δ 2.02 (s, CH3C(O)), 3.08 (s, HC≡C), 3.27–3.46 (m, CH2N3), 3.56 (dd, J = 7.5, 9.6
Hz, OCHH’), 3.61–3.76 (m, CH2CH2O), 3.91 (dd, J = 3.6, 9.6 Hz, OCHH’), 4.45 (d, J = 6.0
Hz, CH2N), 4.56–4.63 (m, CH), 6.54 (d, J = 6.0 Hz, NH), 6.95–7.05 (br t, CH2NH), 7.22 (d,
J = 7.9 Hz, 2 ArH), 7.45 (d, J = 7.9 Hz, 2 ArH); 13C NMR (CDCl3) δ 23.1 (CH3C(O)), 43.2
(CH2N), 50.6 (CH2N3), 52.4 (CH), 70.1, 70.2 (2 CH2O), 77.3 (C≡C), 83.2 (C≡C), 121.2,
127.4, 132.3, 138.7 (4 ArC), 169.8, 170.4 (2 C(O)); Mr (+ESI) 352.1387 [M+Na]+ (calcd for
C16H19N5O3Na+ 352.1386 [M+Na]+).
(R)-N-(4-Ethynyl)benzyl) 2-Acetamido-3-(2-isothiocyanato-ethoxy)propionamide ((R)-10)
Triphenylphosphine polymer bound (Fluka, cat # 93094) (1.6 mol/g, 3.0 mmol) was added to
an aqueous (180 μL, 10.0 mmol)/THF (10 mL) solution of (R)-24 (329 mg, 1.0 mmol). The
mixture was shaken until the starting material was no longer evident by TLC analysis (18 h).
The triphenylphosphine-based support was filtered, washed with CH2Cl2, and the filtrate was
concentrated in vacuum to obtain the free amine (R)-26: 1H NMR (CDCl3) δ 2.03 (s, CH3C
(O)), 2.76-2.92 (m, CH2NH2), 3.07 (s, HC≡C), 3.48–3.62 (m, OCHH’, CH2O), 3.84 (dd, J =
4.2, 10.2 Hz, OCHH’), 4.39–4.52 (m, CH2N), 4.54–4.60 (m, CH), 6.71–6.79 (br d, CH3C(O)
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NH), 7.23 (d, J = 7.9 Hz, 2 ArH), 7.45 (d, J = 7.9 Hz, 2 ArH), 7.82–7.91 (br m,
NHCH2); 13C NMR (CD3CN) δ 23.1 (CH3CO), 42.5, 43.2 (2 CH2N), 54.7 (CH), 71.2, 74.2
(2 CH2O), 78.7 (C≡C), 84.2 (C≡C), 121.5, 128.3, 133.0, 141.7 (ArC), 171.2, 171.4 (2 C(O)).
Anhydrous CH2Cl2 (5 mL) was added to the free amine (R)-26 and DPT (232 mg, 1.0 mmol)
was added. The yellow solution was stirred at room temperature (18 h). The solvent was
evaporated under reduced pressure and the residue was purified by silica gel column
chromatography (EtOAc to 90/10 EtOAc/MeOH) to obtain (R)-10 as a white solid (80 mg,
23%); Rf = 0.45 (EtOAc); mp 124–126 °C; [α]25D +8.0° (c 0.5, DMSO); IR (nujol mull) 3266,
2571, 2201, 2103, 1631, 1538, 1458, 1375, 1304, 1120, 820, 725 cm−1; 1H NMR (CDCl3) δ
2.08 (s, CH3C(O)), 3.07 (s, HC≡C), 3.55–3.77 (m, CH2NCS, OCHH’, CH2CH2O), 4.01 (dd,
J = 3.3, 9.3 Hz, OCHH’), 4.43–4.57 (m, CH2N), 4.58–4.64 (m, CH), 6.54 (d, J = 6.3 Hz,
CH3C(O)NH), 6.79–6.88 (br t, NHCH2), 7.25 (d, J = 8.6 Hz, 2 ArH), 7.46 (d, J = 8.6 Hz, 2
ArH); 13C NMR (CDCl3) δ 23.3 (CH3CO), 43.3 (CH2N), 45.4 (CH2NCS), 52.7 (CH), 69.3,
70.0 (2 CH2O), 77.4 (C≡C), 83.3 (C≡C), 121.3, 127.5, 132.4, 138.8 (4 ArC), 169.7, 170.6 (2
C(O)), the signal for the isothiocyanate carbon resonance was not detected under the conditions
used for the acquisition of the NMR spectrum; Mr (+ESI) 368.1048 [M+Na]+ (calcd for
C17H19N3O3SNa+ 368.1045 [M+Na]+). Anal. (C17H19N3O3S•0.2H2O): C, H, N, S.
(S)-N-(4-Ethynyl)benzyl) 2-Acetamido-3-(2-isothiocyanato-ethoxy)propionamide ((S)-10)
Utilizing the preceding procedure, polymer bound (Fluka, cat # 93094) (1.6 mol/g, 3.3 mmol),
H2O (205 μL, 11.4 mmol)/THF (10 mL) solution, and (S)-24 (375 mg, 1.1 mmol) gave the free
amine (S)-26; 1H NMR (CDCl3) δ 2.01 (s, CH3C(O)), 2.77–2.91 (m, CH2NH2), 3.07 (s,
HC≡C), 3.49–3.57 (m, OCHH’, CH2O), 3.80 (dd, J = 4.5, 9.9 Hz, OCHH’), 4.38–4.51 (m,
CH2N), 4.56–4.62 (m, CH), 6.88 (d, J = 6.9 Hz, CH3C(O)NH), 7.23 (d, J = 8.7 Hz, 2 ArH),
7.45 (d, J = 8.7 Hz, 2 ArH), 7.88–8.01 (br t, NHCH2); Mr (+ESI) 304.1662 [M+H]+ (calcd for
C16H21N3O3H+ 304.1661 [M+H]+).
Utilizing the preceding procedure, the free amine (S)-26 was coupled with DPT (125 mg, 32%)
to give (S)-10: Rf = 0.45 (EtOAc); mp 127 °C; [α]25D −9.6° (c 0.5, DMSO); IR (nujol mull)
3277, 2730, 2208, 2107, 1635, 1549, 1458, 1375, 1307, 1130, 819, 726 cm−1; 1H NMR
(CDCl3) δ 2.07 (s, CH3C(O)), 3.07 (s, HC≡C), 3.53–3.77 (m, CH2NCS, OCHH’,
CH2CH2O), 4.00 (dd, J = 3.3, 9.3 Hz, OCHH’), 4.42–4.56 (m, CH2N), 4.59–4.64 (m, CH),
6.55 (d, J = 6.9 Hz, CH3C(O)NH), 6.81-6.85 (br t, NHCH2), 7.24 (d, J = 8.4 Hz, 2 ArH), 7.46
(d, J = 8.4 Hz, 2 ArH); 13C NMR (CDCl3) δ 23.2 (CH3CO), 43.3 (CH2N), 45.4 (CH2NCS),
52.7 (CH), 69.3, 70.0 (2 CH2O), 77.3 (C≡C), 83.3 (C≡C), 121.3, 127.5, 132.4, 138.7 (4
ArC), 169.7, 170.6 (2 C(O)), the signal for the isothiocyanate carbon resonance was not
detected under the conditions used for the acquisition of the NMR spectrum; Mr (+ESI)
368.1046 [M+Na]+ (calcd for C17H19N3O3SNa+ 368.1045 [M+Na]+). Anal.
(C17H19N3O3S•0.16CH3OH): C, H, N, S.
Preparative Reaction of (R)-N-(4-Isothiocyanato)benzyl) 2-Acetamido-3-(prop-2-ynyloxy)
propionamide ((R)-9) and N-2-(2-(2-(2-Azidoethoxy)ethoxy)ethoxy)ethyl Biotin Amide (35) to
Give (R)-36
(R)-9 (50 mg, 0.15 mmol) and 35 (81 mg, 0.18 mmol) were dissolved in t-BuOH/H2O (1:2, 3
mL) and then a freshly prepared aqueous 1 M sodium ascorbate solution (15 μL, 15.0 mol)
was added, followed by a freshly prepared aqueous 0.1 M CuSO4·5H2O solution (15 μL, 1.5
μmol). The reaction mixture was vigorously stirred at room temperature (15 h), evaporated in
vacuo, and then purified by column chromatography (SiO2; 1/9 MeOH/CHCl3) to yield 60 mg
(51%) of (R)-36 as a white sticky foam: Rf = 0.30 (1/9 MeOH/CHCl3); IR (nujol) 3284, 2925,
2108, 1657, 1544, 1459 cm−1; 1H NMR (CDCl3) δ 1.37-1.44 (m, C(6)H2), 1.55-1.67 (m,
CH2CH2C(6)), 2.02 (s, CH3C(O)), 2.14 (t, J = 7.5 Hz, C(10)CH2), 2.70 (d, J = 12.6 Hz, C(5)
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HH’), 2.89 (dd, J = 4.8, 12.6 Hz, C(5)HH’), 3.09-3.15 (m, C(2)H), 3.38-3.41 (m,
OCH2CH2NHC(O)), 3.52-3.62 (m, 2 OCH2CH2O, triazole-CH2CH2O), 3.67 (dd, J = 6.5, 9.8
Hz, CHCHH’OCH2), 3.86-3.94 (m, OCH2CH2NHC(O), CHCHH’OCH2), 4.25-4.30 (m, C(3)
H), 4.40-4.49 (m, CH2Ar, C(4)H), 4.55 (t, J = 5.0 Hz, triazole-CH2CH2O), 4.62-4.68 (m,
CHCH2OCH2-triazole, CHCH2OCH2-triazole), 5.57, 6.52 (s, N(1′)H, N(3′)H), 6.84 (t, J = 5.4
Hz, OCH2CH2NHC(O)), 7.10-7.15 (m, 2 ArH), 7.24 (d, J = 8.7 Hz, 2 ArH), 7.40 (d, J = 7.5
Hz, CH3C(O)NHCH), 7.80 (s, CH triazole), 7.83 (t, J = 6.0 Hz, NHCH2Ar); 13C NMR
(CD3OD) δ 23.3 (CH3C(O)), 25.7 (C(6)), 28.3 (C(7)), 28.4 (C(8)), 35.9 (C(9)), 39.3
(OCH2CH2NHC(O)), 40.8 (C(5)), 43.0 (CH2Ar), 50.4 (triazole-CH2CH2O), 53.2
(CHCH2OCH2-triazole), 55.8 (C(2)), 60.3 (C(3)), 62.1 (C(4)), 64.6 (CHCH2OCH2-triazole),
69.5 (CHCH2OCH2-triazole), 70.0, 70.1, 70.2, 70.4, 70.5, 70.6 (3 CH2OCH2 in PEG linker),
124.3 (triazole CH), 126.0, 128.7, 130.1, 138.1 (C6H4), 135.4 (NCS), 144.3 (triazole C), 164.1,




Compound (R)-30 (400 mg, 1.3 mmol) was dissolved in a THF:H2O mixture (1:1, 50 mL) and
while stirring, propargyl methyl ether (1 mL, 11.8 mmol), sodium ascorbate (25 mg, 0.13
mmol), and CuSO4 (3 mg, 0.01 mmol), were successively added. The reaction was stirred at
room temperature (24 h), and saturated aqueous NaHCO3 (100 mL) was added. The aqueous
layer was extracted with CH2Cl2 (2 × 100 mL), the combined organic layers were washed with
brine (100 mL) and filtered through a Celite® bed. Removal of solvents in vacuo gave an off-
white solid that was purified by flash chromatography (10/90 MeOH/CH2Cl2) to yield
(R)-38 (470 mg, 96%) as a crystalline solid: mp 127-129 °C; [α]25D +1.8° (c 0.34; MeOH);
Rf = 0.49 (10/90 MeOH/CH2Cl2); IR (nujol mull) 3296, 2861, 1641, 1545, 1457, 1377, 1143,
1095 cm−1; 1H NMR (CDCl3) δ 2.00 (s, CH3C(O)), 3.38 (s, CH2OCH3), 3.50 (dd, J = 6.5, 9.6
Hz, CHH’OCH2CH2), 3.76–3.85 (m, OCH2CH2N(N)CH), 3.92 (dd, J = 4.2, 9.6 Hz,
CHH’OCH2CH2), 4.34–4.51 (m, NHCH2Ph, OCH2CH2N(N)CH, CH2OCH3), 6.63 (d, J =
6.6 Hz, NHCHC(O)), 7.00–7.10 (br t, NHCH2Ph), 7.18–7.35 (m, C6H5), 7.52 (s, NCHC(N)),
addition of excess (R)-(−)-mandelic acid to a CDCl3 solution of (R)-38 gave only one signal
for the acetyl protons; 13C NMR (CDCl3)  23.2 (CH3C(O)), 43.7 (NHCH2Ph), 50.0 (CH2N
(N)CH), 52.9 (CHC(O)NH), 58.6 (CH2OCH3), 66.0 (OCH2CH2N), 69.4, 70.5
(CHCH2OCH2, CH2OCH3), 123.8 (NCHC(N)), 127.6, 127.7, 128.8, 138.3 (C6H5), 145.3
(NCHC(N)), 169.7, 170.8 (CH3C(O), CHC(O)NH); Mr (+ESI) 398.1806 [M+Na]+ (calcd for
C18H25N5O4Na+ 398.1804 [M+Na]+). Anal. (C18H25N5O4) C, H, N.
Preparation of Mouse Soluble Brain Proteosomes
Mouse brains (male, 2 months, ICR mice [Rockland Immunochemicals, Gilbertsville, PA])
were Dounce-homogenized in 50 mM HEPES buffer (pH 7.4). The lysate was centrifuged at
slow speed (1200 × g for 12 min at 4 °C) to remove debris. The supernatant was then centrifuged
at high speed (100,000 × g for 1 h at 4 °C). The resulting supernatant was collected and stored
at −80 °C until use. The total protein concentration was determined by using the Bradford
assay.
Three NCS Probe Labeling, Cycloaddition Reaction, and In-Gel Fluorescence Scanning
Mouse brain lysate (1 mL, 50 mM HEPES buffer (pH 7.4)) was passed through a NAP-10
column (GE Healthcare) to exchange buffer to an aqueous 50 mM HEPES buffer (pH 8.0).
Lysate aliquots (50 μL of 2.0 mg/mL protein in 50 mM HEPES buffer (pH 8.0)) were treated
with lacosamide AB (NCS) & CR (alkyne, N3) compounds (5 μM) at room temperature (30
min). The modified lysates were sequentially treated with rhodamine reporter tag (50 μM)
Park et al. Page 19













(either rhodamine-azide (Rho-N3, 39) or rhodamine-alkyne (Rho-PEG-≡, 40)), TCEP (1 mM),
TBTA (200 μM) and CuSO4 (1 mM). Samples were shaken and allowed to rotate using Roto-
shake (8 rpm, Scientific Industries Inc., Model No. SI-1100, Bohemia, NY) at room
temperature (1 h). Proteins were separated by SDS-PAGE after addition of 4× SDS-PAGE
loading buffer and visualized by in-gel fluorescence using a typhoon 9400 scanner (GE
Healthcare/Amersham Bioscience) with excitation at 555 nm and detection at 580 nm.
Probe Labeling of GST-CRMP2 in Mouse Lysate, Cycloaddition, and In-Gel Fluorescence
Scanning
Utilizing the previous method, lysate aliquots (150 μL, pH 8.0) were prepared after passage
through a NAP-10 column. Overexpressed GST-CRMP2 (30 μg) was added to the lysate (150
μL) and divided into three equal aliquots. The aliquots (50 μL) were treated with (R)- and
(S)-9 (5 μM) at room temperature (30 min). Using the previous method, the modified lysates
were then treated with 39 under Cu(I)-mediated cycloaddition conditions, followed by SDS-
PAGE separation, and in-gel fluorescence.
Pharmacology
Compounds were screened under the auspices of the National Institutes of Health’s
Anticonvulsant Screening Program. Experiments were performed in male rodents [albino
Carworth Farms No. 1 mice (intraperitoneal route, ip), albino Spague-Dawley rats (oral route,
po)]. Housing, handling, and feeding were in accordance with recommendations contained in
the ‘Guide for the Care and Use of laboratory Animals’. Anticonvulsant activity was
established using the MES test59,60 and the scMet test,59 using previously reported methods.
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“Affinity Bait” and “Chemical Reporter” (AB&CR) Strategy to Scan the Brain Proteome for
(R)-Lacosamide Target(s)
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General Synthetic Pathway to Prepare Lacosamide AB&CR Agents 9–11
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Chemical evaluation of the AB and the CR units in 3
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Proteome reactivity profiles of three different isothiocyanate (NCS) agents 9–11.
Figure 2A; AB&CR agent-labeled proteins were detected by in-gel fluorescence scanning after
Cu(I)-mediated cycloaddition to either a rhodamine-azide reporter probe 39 or a rodamine-
alkyne reporter probe 40. Figure 2B; CRMP2 protein was detected by western blot using anti-
CRMP2. Figure 2C; All proteins in lysate were visualized by Coomassie blue staining after
in-gel fluorescence scanning. (All images shown in gray scale).
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In vitro labeling of externally added GST-CRMP2 and endogenous CRMP2 in mixture of
mouse lysate and overexpressed GST-CRMP2.
Figure 3A; AB&CR agent-labeled proteins were detected by in-gel fluorescence scanning after
Cu(I)-mediated cycloaddition to rhodamine-azide reporter probe 39. Figure 3B; CRMP2 and
GST proteins were detected by western blot using anti-CRMP2 and anti-GST antibodies.
Figure 3C; All proteins in lysate were visualized by Coomassie blue staining after in-gel
fluorescence scanning. (All images shown in gray scale).
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